Literature DB >> 20187901

Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II.

Joachim Klode1, Joachim Dissemond, Stephan Grabbe, Uwe Hillen, Thorsten Poeppel, Carsten Boeing.   

Abstract

BACKGROUND AND OBJECTIVES: Sentinel lymph node excision (SLNE) for the detection of regional nodal metastases and staging of malignant melanoma has resulted in some controversies in international discussions. Positron emission tomography with computerized tomography (PET-CT), a noninvasive imaging procedure for the detection of regional nodal metastases, has increasingly become of interest. Our study is a direct comparison of SLNE and PET-CT in patients with early-stage malignant melanoma.
MATERIALS AND METHODS: We retrospectively analyzed data from 61 patients with primary malignant melanoma with a Breslow index greater than 1.0 mm.
RESULTS: Metastatic SLNs were found in 14 patients (23%); 17 metastatic lymph nodes were detected overall, only one of which was identified preoperatively using PET-CT. Thus, PET-CT showed a sensitivity of 5.9% and a negative predictive value of 78%.
CONCLUSION: SLNE is much more sensitive than PET-CT in discovering small lymph node metastases. We consider PET-CT unsuitable for the evaluation of early regional lymphatic tumor dissemination in this patient population and recommend that it be limited to malignant melanomas of American Joint Committee on Cancer stages III and IV. We therefore recommend the routine use of SLNE for tumor staging and stratification for adjuvant therapy of patients with stage I and II malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187901     DOI: 10.1111/j.1524-4725.2010.01479.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

Review 1.  Preclinical lymphatic imaging.

Authors:  Fan Zhang; Gang Niu; Guangming Lu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

2.  PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.

Authors:  Thomas Pfluger; Henriette Ingrid Melzer; Vera Schneider; Christian La Fougere; Eva Coppenrath; Carola Berking; Peter Bartenstein; Mayo Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

3.  Comparison between F-Fluorodeoxyglucose Positron Emission Tomography and Sentinel Lymph Node Biopsy for Regional Lymph Nodal Staging in Patients with Melanoma: A Review of the Literature.

Authors:  Paoletta Mirk; Giorgio Treglia; Marco Salsano; Pietro Basile; Alessandro Giordano; Lorenzo Bonomo
Journal:  Radiol Res Pract       Date:  2011-12-22

4.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

5.  Usefulness of 18F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels.

Authors:  Özge Vural Topuz; Fatma Arzu Görtan; Zübeyde Rana Kaya Döner; Çetin Önsel; Haluk Burçak Sayman
Journal:  Mol Imaging Radionucl Ther       Date:  2018-06-07

6.  Significance of PET-CT for Detecting Occult Lymph Node Metastasis and Affecting Prognosis in Early-Stage Tongue Squamous Cell Carcinoma.

Authors:  Guo Zhao; Jianli Sun; Kai Ba; Yunxiang Zhang
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

7.  Malignant melanoma.

Authors:  Aída Ortega Candil; Cristina Rodríguez Rey; José Luis Carreras Delgado
Journal:  ISRN Dermatol       Date:  2012-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.